Drug Recalls

The U.S. Food and Drug Administration (FDA) keeps track of drug recalls and safety alerts. Below is a list of drug recalls that could affect you.

Call Member Services at 1-888-276-2020 or talk to your doctor to find out more.




  • December 20, 2018Terrific Care, LLC. / Medex Supply Dist, Inc. issues Nationwide Recall of CoaguChek Test Strips
  • August 9, 2018Westminster Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration
    Westminster Pharmaceuticals LLC is voluntarily recalling all lots, within expiry, of levothyroxine and liothyronine (thyroid tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s import alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with current good manufacturing practices (cGMP). Substandard cGMP practices could represent the possibility of risk being introduced into the manufacturing process. To date, Westminster Pharmaceuticals has not received any reports of adverse events related to this product.
  • July 17, 2018Valsartan and Valsartan HCTZ
    Prinston Pharmaceutical Inc., dba Solco Healthcare LLC., is voluntarily recalling all lots of Valsartan tablets, 40 mg, 80 mg, 160 mg, and 320 mg; and Valsartan-hydrochlorothiazide tablets, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg to the consumer level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), in an active pharmaceutical ingredient by the manufacturer — Zhejiang Huahai Pharmaceutical Co. Ltd. — in the manufacture of the subject product lots.
  • March 2, 2018Zinbryta®
    On March 2, Biogen® and Abbvie announced a voluntary withdrawal of Zinbryta (daclizumab), a multiple sclerosis (MS) drug, from the global market, noting concern about the drug’s evolving benefit/risk profile. As a result, FDA is working closely with the manufacturers to help ensure a well-organized withdrawal from the market in the United States, and to ensure that health care professionals have the information they need to carefully transition their patients using Zinbryta to another treatment.